Libmeldy是一款基于慢病毒 载体 和自体CD34+细胞的基因疗法，于2018年4月从 葛兰素史克 （GSK）收购。该疗法由含有造血 干细胞 和祖细胞（HSPC）的自体 ...

人们对 CD34 阳性造血干细胞的重视无意中忽略了 CD34 阴性造血干细胞，后者大多存在于脐带血中，虽然在血液中的迁移能力有限，但由于其发育状态 ...

这一创新技术可高效转染诱导多能干细胞（iPSC）、人CD34+造血干细胞、h1人胚胎干细胞等难转染细胞，为干细胞基因递送提供了全新方案。 表1.

In CD34-positive AML, the leukemic stem cell has been recognized as CD38 negative. This CD34+CD38− population survives chemotherapy and is most probable the cause of minimal residual disease (MRD).

Original Article Published: 22 May 2017 CD34+ cells from dental pulp stem cells with a ZFN-mediated and homology-driven repair-mediated locus-specific knock-in of an artificial β-globin gene S ...

These findings show that CD34+33- cells are readily collected in most cancer patients and significantly influence engraftment kinetics and transfusion requirements in autologous blood stem-cell ...

Based on data from 59 patients, we calculated for each day after PBSC transplantation the dose of CD34+ cells that resulted in rapid recovery of either neutrophils or platelets in the majority (> 70%) ...

OrganaBio's HematoPAC™-HSC-CB CD34+ hematopoietic stem cells (HSCs) are isolated from fresh cord blood, within hours of birth. HematoPAC™-HSC-CBs are supported by a comprehensive quality data ...

CD34+ HSPCs were edited by means of CRISPR-Cas9 with a guide mRNA. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan.

Infused CD34+ cells had mean VCNs of 1.6 to 3.9 copies per cell and generally higher VCNs in differentiated T lymphocytes (1.5 to 5.0 copies per cell) and B lymphocytes (1.5 to 5.2 copies per cell ...

Ryan Huang, CEO of Beauty-Stem Biomedical, and Dr. David Chen, director of Diagnostic Medical Group of Southern California, delivered a compelling presentation highlighting the numerous benefits ...

For patients with MM and lymphoma, the success rates of CD34+ cell acquisition were 73.6% and 58.7%, ideal rates were 43.4% and 30.7%, and failure rates were 26.4% and 41.3%, according to the study.